期刊
PHARMACOECONOMICS
卷 38, 期 2, 页码 135-141出版社
ADIS INT LTD
DOI: 10.1007/s40273-019-00869-3
关键词
-
资金
- Canadian Institutes of Health Research (CIHR)
- Genome Canada
- University of Alberta
- Canadian Agency for Drugs and Technology in Health (CADTH)
- Capital Health Research Chair Endowment at the University of Alberta
Although probabilistic analysis has become the accepted standard for decision analytic cost-effectiveness models, deterministic one-way sensitivity analysis continues to be used to meet the need of decision makers to understand the impact that changing the value taken by one specific parameter has on the results of the analysis. The value of a probabilistic form of one-way sensitivity analysis has been recognised, but the proposed methods are computationally intensive. Deterministic one-way sensitivity analysis provides decision makers with biased and incomplete information whereas, in contrast, probabilistic one-way sensitivity analysis (POSA) can overcome these limitations, an observation supported in this study by results obtained when these methods were applied to a previously published cost-effectiveness analysis to produce a conditional incremental expected net benefit curve. The application of POSA will provide decision makers with unbiased information on how the expected net benefit is affected by a parameter taking on a specific value and the probability that the specific value will be observed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据